Table 3 sPSA detection rate in post-menopausal breast cancer patients (n = 117)
From: Clinical significance of serum PSA in breast cancer patients
| n | sPSA positive (%) | sPSA negative (%) | p value | |
|---|---|---|---|---|
| Clinical stage | 0.0072 | |||
| Non-MBC; Stage 0-III | 45 | 6 (13.3) | 39 (86.7) | |
| MBC; Stage VI, Recurrence | 72 | 26 (36.1) | 46 (63.9) | |
| Histological type | 0.9320 | |||
| Invasive ductal carcinoma | 82 | 21 (25.6) | 61 (74.4) | |
| Ductal carcinoma in situ | 6 | 2 (33.3) | 4 (66.7) | |
| Invasive lobular carcinoma | 10 | 3 (30.0) | 7 (70.0) | |
| Special type | 19 | 6 (31.6) | 13 (68.4) | |
| Subtype | 0.3028 | |||
| Luminal; ER+ / HER2- | 83 | 19 (22.9) | 64 (77.1) | |
| Luminal HER2; ER+ / HER2+ | 13 | 6 (46.2) | 7 (53.8) | |
| HER2 enriched; ER- / HER2+ | 7 | 2 (28.6) | 5 (71.4) | |
| TNBC; ER- / HER2- | 14 | 5 (35.7) | 9 (64.3) | |
| Androgen receptor | 0.0034 | |||
| < 20% | 55 | 8 (14.5) | 47 (85.5) | |
| ≥ 20% | 59 | 23 (39.0) | 36 (61.0) | |
| Unknown | 3 | 1 (33.3) | 2 (66.7) | |
| PSA (IHC of primary lesion) | 0.1271 | |||
| Positive | 64 | 21 (32.8) | 43 (67.2) | |
| Negative | 50 | 10 (20.0) | 40 (80.0) | |
| Unknown | 3 | 1 (33.3) | 2 (66.7) | |
| Nuclear grade | 0.7405 | |||
| 1 | 67 | 18 (26.9) | 49 (73.1) | |
| 2 | 36 | 9 (25.0) | 27 (75.0) | |
| 3 | 14 | 5 (35.7) | 9 (64.3) | |
| Ki67 (LI) | 0.0400 | |||
| < 20% | 52 | 19 (36.5) | 33 (63.5) | |
| ≥ 20% | 62 | 12 (19.4) | 50 (80.6) | |
| Unknown | 3 | 1 (33.3) | 2 (66.7) | |
